Polypeptide marker for Alzheimer's disease and its use for diagnosis
AssigneeUniversity of California
InventorsGeorge G. Glenner, Caine W. Wong
Life of this patent
Estimating the term…
Abstract
A novel polypeptide, Alzheimer's Amyloid Polypeptide (AAP), is provided in substantially purified form which is isolated from amyloid deposits in patients with Alzheimer's Disease. The polypeptide has the following amino acid sequence: ##STR1## The polypeptide, or fragments thereof, may be used to produce antibodies useful in a diagnostic test for Alzheimer's Disease. Nucleotide probes corresponding to portions of the polypeptide are also useful for diagnostic purposes.
Claims41
A substantially purified polypeptide isolated from patients with Alzheimer's Disease, Alzheimer's Amyloid Polypeptide, having the following amino acid sequence:
- ##STR6##
A reagent for use in the diagnosis of Alzheimer's Disease in a human patient, comprising antibodies obtained by means of an immune response to exposure to the substantially purified polypeptide isolated from patients with Alzheimer's Disease, Alzheimer's Amyloid Polypeptide, having the following amino acid sequence:
- ##STR7##
A diagnostic method for determining the presence of Alzheimer's Disease in a human patient by detecting the presence of Alzheimer's Amyloid Polypeptide in the patient through an immunoassay, comprising the steps of:
- a. combining a sample of the human patient's body fluid suspected of containing Alzheimer's Amyloid Polypeptide with antibodies specific to Alzheimer's Amyloid Polypeptide, having the following amino acid sequence:
- ##STR8## b. monitoring the combination of step a. to determine whether said antibodies have bound to said Alzheimer's Amyloid Polypeptide in an immunological reaction, thereby indicating that said patient has Alzheimer's Disease.
A diagnostic method for determining the presence of Alzheimer's Disease in a human patient by histological localization of Alzheimer's Amyloid Polypeptide, comprising the steps of:
- a. combining a sample of the human patient's tissue with antibodies specific to Alzheimer's Amyloid Polypeptide, having the following amino acid sequence:
- ##STR9## b. monitoring the combination of step a. to determine whether said antibodies have bound to said Alzheimer's Amyloid Polypeptide in an immunological reaction, thereby indicating that said patient has Alzheimer's Disease.
A labelled nucleotide probe, comprising a sequence of nucleic acid substantially complementary to the nucleotide sequence coding for the substantially purified polypeptide isolated from patients with Alzheimer's Disease, Alzheimer's Amyloid Polypeptide, having the following amino acid sequence:
- ##STR10##
An immunogenic peptide fragment of a substantially purified polypeptide isolated from patients with Alzheimer's Disease, Alzheimer's Amyloid Polypeptide, comprising:
- a linear sequence of amino acids corresponding to any subsequence of the following amino acid sequence:
- ##STR12## said linear sequence being immunogenic so as to induce the production of active antibodies specific to Alzheimer's Amyloid Polypeptide.
Dependencies are inferred from the claim text.